Decibel Therapeutics Reports Fourth Quarter and Full Year
- Key anticipated catalysts in 2022 include submission of IND and/or CTA for DB-OTO and results from interim analysis from Phase 1b trial of DB-020 for cisplatin-induced hearing loss - ...
ADVERTISEMENT
Tag: Nasdaq:DBTX
Decibel Therapeutics to Participate in the 11th Annual SVB
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today ...
Decibel Therapeutics Reports on Continued Progress of Lead
- Podium presentation at Association for Research in Otolaryngology Annual MidWinter Meeting highlighting DB-OTO dose-ranging studies with expression analysis, functional recovery and tolerability data - - Podium presentation and posters ...
Decibel Therapeutics Announces Publication of Foundational Study of Noise-related Inner Ear Damage
BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today ...
Copyright © 2015 - 2021 Lifecarenews.in